**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 59574

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study**

Glapa-Nowak A *et al*. APOE polymorphisms in inflammatory bowel disease

Aleksandra Glapa-Nowak, Mariusz Szczepanik, Barbara Iwańczak, Jarosław Kwiecień, Anna Barbara Szaflarska-Popławska, Urszula Grzybowska-Chlebowczyk, Marcin Osiecki, Marcin Dziekiewicz, Andrzej Stawarski, Jaroslaw Kierkus, Tomasz Banasiewicz, Aleksandra Banaszkiewicz, Jarosław Walkowiak

**Aleksandra Glapa-Nowak, Mariusz Szczepanik, Jarosław Walkowiak,** Department of Pediatric Gastroenterology and Metabolic Diseases, Poznań University of Medical Sciences, Poznań 60-572, Poland

**Barbara Iwańczak,** Department of Pediatrics, Medical University of Wroclaw, Wroclaw 50-369, Poland

**Jarosław Kwiecień,** Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze 41-800, Poland

**Anna Szaflarska-Popławska,** Department of Pediatric Endoscopy and Gastrointestinal Function Testing, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz 86-067, Poland

**Urszula Grzybowska-Chlebowczyk,** Department of Pediatrics, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Katowice 40-752, Poland

**Marcin Osiecki,** **Jarosław Kierkuś,** Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children’s Memorial Health Institute, Warsaw 04-730, Poland

**Marcin Dziekiewicz, Aleksandra Banaszkiewicz,** Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw 02-091, Poland

**Andrzej Stawarski,** Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw 50-369, Poland

**Tomasz Banasiewicz,** Chair and Department of General Surgery, Gastroenterological Surgical Oncology and Plastic Surgery, Poznań University of Medical Sciences, Poznań 60-355, Poland

**Author contributions:** Glapa-Nowak A, Szczepanik M, and Walkowiak J contributed to conceptualization and administration; Glapa-Nowak A and Walkowiak J contributed toformal analysis and funding acquisition; Szczepanik M, and Walkowiak J designed and coordinated the study; Glapa-Nowak A, Szczepanik M, Iwańczak B, Kwiecien J, Szaflarska-Popławska AB, Grzybowska-Chlebowczyk U, Osiecki M, Dziekiewicz M, Stawarski A, Kierkus J, Banasiewicz T, and Banaszkiewicz A wrote the manuscript and acquired and analysed data; All authors approved the final version of the article.

**Supported by** the National Science Centre, Poland, No. 2017/25/B/NZ5/02783 (to Walkowiak J).

**Corresponding author: Jarosław Walkowiak, MD, PhD, Professor,** Department of Pediatric Gastroenterology and Metabolic Diseases, Poznań University of Medical Sciences, Szpitalna Street 27/33, Poznań 60-572, Poland. jarwalk@ump.edu.pl

**Received:** September 18, 2020

**Revised:** November 17, 2020

**Accepted:** February 25, 2021

**Published online:**

**Abstract**

BACKGROUND

It has been suggested that apolipoprotein E (*APOE)* polymorphisms are associated with the risk of developing inflammatory bowel disease (IBD) and the early age of disease onset. However, there are no reports regarding the relationship with clinical characteristics and disease severity.

AIM

To summarise thatAPOEpolymorphisms are associated with the risk of developing IBD and the early age of disease onset.

METHODS

In total,406 patients aged 3-18 with IBD (192 had ulcerative colitis and 214 had Crohn’s disease) were genotyped using the TaqMan hydrolysis probe assay. Clinical expression was described at diagnosis and the worst flare by disease activity scales, albumin and C-reactive protein levels, localisation and behaviour (Paris classification). Systemic steroid intake with the total number of courses, immunosuppressive, biological, and surgical treatment with the time and age of the first intervention were determined. The total number of exacerbation-caused hospitalisations, the number of days spent in hospital due to exacerbation, the number of relapses, and severe relapses were also estimated.

RESULTS

Ulcerative colitis patients with the *APOEε4* allele had lower C-reactive protein values at diagnosis (*P* = 0.0435) and the worst flare (*P* = 0.0013) compared to patients with the *APOEε2* allele and genotype *APOEε3/ε3*. Crohn’s disease patients with the *APOEε2* allele scored lower on the Pediatric Crohn’s Disease Activity Index at diagnosis (*P* = 0.0204). IBD patients with *APOEε2* allele spent fewer days in the hospital due to relapse (*P* = 0.0440).

CONCLUSION

*APOE* polymorphisms are associated with the risk of developing IBD and the clinical expression of IBD. However, the clinical relevance of the differences identified is rather modest.

**Key Words:** Apolipoprotein E polymorphism; Crohn’s disease; Ulcerative colitis; Immunosuppression; Surgery; Disease severity

Glapa-Nowak A, Szczepanik M, Iwańczak B, Kwiecień J, Szaflarska-Popławska A, Grzybowska-Chlebowczyk U, Osiecki M, Dziekiewicz M, Stawarski A, Kierkuś J, Banasiewicz T, Banaszkiewicz A, Walkowiak J. Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study. *World J Gastroenterol* 2021; In press

**Core Tip:** Apolipoprotein E polymorphisms are associated with the risk of developing inflammatory bowel disease and seem to be associated with the disease expression and treatment. However, the clinical relevance of the differences is relatively modest.

**INTRODUCTION**

Heritability and disease risk can only be partly explained by genetic factors alone[1-4]. Inflammatory bowel disease (IBD) has a strong genetic makeup. To date, 240 risk gene loci have been associated with the disease[1]. Several genetic variations are linked to specific IBD phenotypes. For instance, *NOD2*, *IRGM*, *ATG16L1*, and *NCF4/NCF2* are related to segmental, structuring, or early-onset disease[5-10]. Genetic testing for these and other variants may prove useful in predicting the disease course for future clinical use.

One of the well-known genetic determinants of some diseases other than IBD isapolipoprotein E (*APOE*), most commonly known for its role in Alzheimer’s disease[11]. Although first recognised for its role in lipoprotein metabolism, APOE is involved in several biological processes not directly related to lipid transport function[12]. Importantly, APOE is a key player in immunoregulation[13-15] and associated with autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and psoriasis[16-18]. It has been reported that APOE has several immune-related functions such as suppressing T-cell proliferation[19-21], possibly by downregulating DNA synthesis and reducing phospholipid turnover in T cells[22-24], neutrophil activation[25], and modulation of macrophage assisted[26-28] antigen presentation[14,15].

APOE is a polymorphic protein present in three major isoforms that differ only by two single amino acid substitutions, APOE*ε*4 (arg112, arg158), APOE*ε*3 (cys112, arg158), and APOE*ε*2 (cys112, cys158). The amino acid replacement causes profound functional changes at the cellular and molecular level as well as in the immune system. APOE suppresses the production of proinflammatory cytokines such as tumour necrosis factor-α in microglia in an isoform-dependent manner (ε2 > ε3 > ε4)[29]. In turn, inflammatory cytokines can promote APOE synthesis and release or downregulate the production of APOE in different tissues[30,31]. However, interactions between APOE and cytokines are occasionally conflicting, highlighting the complex roles of APOE and cytokines in various disorders[15].

In IBD, inflammation alters lipid, apolipoprotein, and lipoprotein profiles in subjects with active disease[32,33] and patients with limited response to infliximab[34]. A previous study from Saudi Arabia showed that the genetic distribution of *APOE* polymorphisms in IBD seems to be altered compared to healthy subjects[35]. The study also suggested that the *ε4* allele increased the risk of IBD and was associated with an early onset of the disease. Similarly, *APOEε4* has been associated with severity in another immunologic disorder: rheumatoid arthritis[16]. For these reasons, this study aimed to investigate the relationship between *APOE* variants with disease severity in IBD.

**MATERIALS AND METHODS**

***Patients***

Patients recruited to the study belonged to the Polish Paediatric Crohn’s and Colitis cohort and involved 406 paediatric IBD patients: 214 with Crohn’s disease (CD; 86 females, 128 males) and 192 with ulcerative colitis (UC; 87 females, 105 males) (Table 1). Patients were recruited in the course of hospital treatment or during scheduled visits at outpatient clinics (Department of Pediatric Gastroenterology and Metabolic Diseases, Poznań University of Medical Sciences; The Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics; The Children’s Memorial Health Institute, Warsaw; Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw; Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University; Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice; Department of Pediatrics, Faculty of Medical Sciences, Medical University of Silesia in Katowice and Department of Pediatric Endoscopy and Gastrointestinal Function Testing, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland). The diagnosis of IBD was confirmed by experienced gastroenterologists using standard diagnostic criteria[36,37]. The inclusion criteria were a diagnosis of CD or UC and aged 3-18. Patients in life-threatening, severe general condition were excluded from the study. The study obtained the approval of the Bioethical Committee at Poznań University of Medical Sciences (960/15 with the associated amendments).

***Disease severity evaluation***

Disease activity was assessed using appropriate scales at diagnosis and the worst flare [Pediatric Ulcerative Colitis Activity Index and Pediatric Crohn’s Disease Activity Index (PCDAI)][38], which was defined by the highest Pediatric Ulcerative Colitis Activity Index and PCDAI scales in their medical history. Albumin (g/dL) and C-reactive protein (CRP; mg/L) concentrations at diagnosis and the worst flare were obtained from medical records (CRP reference range 0-5 mg/L). The treatment domain included data regarding systemic steroid intake with the total number of courses, immunosuppressive treatment with the time and age of the first intake, biological therapy with time and age of first admission, and operative treatment with time and age of first surgery. The localisation and behaviour of the disease were defined by the Paris Classification at the diagnosis and worst flare[39]. Most CD patients presented with an ileocolonic location and nonstricturing behaviour of the disease (Supplementary Table 1), while most UC patients presented with pancolitis and were never severe (S0: > 65 on the Pediatric Ulcerative Colitis Activity Index scale; Supplementary Table 2). Based on medical records, the total number of exacerbation hospitalisations, the number of days spent in hospital due to exacerbation, the number of relapses, and severe relapses from diagnosis were estimated and calculated per year of the disease duration. The associated extraintestinal symptoms and concomitant diseases were collected from the medical history.

***Genotyping***

DNA was isolated from whole blood using the Blood Mini (A and A Biotechnology). A hydrolysis probe assay (TaqMan assay) was used with the following probes, C\_904973\_10 and C\_3084793\_20, to genotype patients (Life Technologies Corp. Carlsbad. California, United States). The genotyping was performed on the CFX-96 thermocycler system with allele discrimination plots provided by CFX Manager Software (Bio-Rad, Hercules, CA, United States).

***Statistical analysis***

Differences in categorical variables were compared with two-tailed Fisher’s exact test. Differences in continuous variables were evaluated by the Mann Whitney *U* test and Kruskal-Wallis test. Post hoc comparisons were performed with Dunn’s test, and the significance level for the time-to-treatment analysis was evaluated by Gehan’s test. The explanatory factor analysis was used to analyse the underlying factors in the questionnaire. The significance level was set at *P* < 0.05, and statistical analyses were performed using Statistica 13.1 software (StatSoft Inc, Tulsa, OK, United States), JASP 0.10.2 (University of Amsterdam, Amsterdam, the Netherlands), and G\*Power (Dusseldorf University, Germany). Comparisons between groups with less than ten patients were not included.

**RESULTS**

***Genotyping***

The most prevalent genotype in UC and CD was *APOEε3/ε3* (Table 2). No differences in the distribution of alleles and genotypes between UC and CD were documented.

The distribution of the *APOE* genotypes was compared to previous studies in the Polish population (Supplementary Table 3). Pooling available data[40-42] to obtain a similar sample size (*n* = 425) showed a significantly lower frequency of *APOEε3/ε3* genotype in IBD patients compared to controls (62.3% *vs* 71.5%; *P* = 0.0051; odds ratio = 0.66; 95% confidence interval: 0.49-0.88) and simultaneously higher frequency of *APOEε3/ε4* genotype (21.7% *vs* 15.1%; *P* = 0.0153; odds ratio = 1.56; 95% confidence interval: 1.09-2.23) with no difference in other genotypes or for the *APOEε3* allele (*P* = 0.8625). However, in the study of Bojar *et al*[43] (postmenopausal women; *n* = 402), the distribution of *APOEε3/ε3* genotype was similar to the present study (62.9% *vs* 62.3%; *P* = 0.8555; odds ratio = 0.97; 95% confidence interval: 0.73-1.30).

UC patients with *APOEε3ε3* had higher CRP values, and the *APOEε2/ε3* genotype were predisposed to left-sided colitis (E2) at diagnosis (Table 3). Concomitant diseases in CD patients occurred at different frequencies in major *APOE* genotypes, and children with *APOEε2ε3* genotype had significantly lower PCDAI scores at diagnosis than patients with the remaining genotypes (Table 4). UC patients with *t*he *APOEε4* allele had significantly lower CRP levels than the patients with *APOEε3ε3* genotype and *APOEε2*-positive, both at diagnosis and at the worst flare (Table 5). There were also differences in age at first biological treatment. Additionally, *APOEε2*-positive patients with IBD spent significantly fewer days in the hospital due to relapse per year of disease duration than *APOEε4*-positive patients and with the *APOEε3/ε3*genotype (Table 5). Patients with CD and *APOEε3ε3* genotype had lower values of standardised body height at diagnosis (Table 5). No difference was observed in the frequency of systemic steroids, immunosuppressive, and biological treatment between *APOE* genotypes in UC and CD patients. Supplementary Table 4 shows the results for the whole group of IBD patients.

**DISCUSSION**

The present study investigated the relationship between *APOE* genotype and disease severity in IBD, suggesting that the *APOE* genotype might be associated with some indices of disease course such as CRP and albumin levels at the worst flare, age at surgery and numbers of hospitalisation days. UC patients with the *APOEε4* allele had the lowest values of CRP, both at diagnosis and the worst flare. The median age at first biological therapy in UC was lowest in patients with the *APOEε4* allele, whereas left-side colitis was more frequent among patients with the *APOEε2* allele. In CD patients, the *APOEε4* allele was associated with higher albumin at worst flare and higher standardised body height at diagnosis. Moreover, patients with the *APOEε2* allele scored lower on the PCDAI. This study is the largest to show the genetic distribution of *APOE* polymorphisms in IBD to date.

APOE is known to be associated with inflammation indicators[13]. The findings of the present study confirm this relationship as the CRP levels differed between *APOE* genotypes. Patients with the *APOEε4* allele and *APOEε3ε4* genotype had lower CRP values at diagnosis and the worst flare, while patients with the *APOEε3ε3* genotype had higher levels of CRP at the worst flare. These results are similar to those obtained in healthy adults, which showed that subjectswith *APOEε3ε3* had the highest plasma levels of CRP and individuals with *APOEε4ε4* and *APOEε2ε4* had the lowest levels[13]. A similar pattern has also been observed in other diseases such as coronary artery disease[43-46]. März *et al*[47] proved that in coronary artery disease, both white cell count and fibrinogen were not related to the *APOE* genotype, suggesting that the underlying mechanism is not associated with inflammation[46] but rather to the mevalonate/cholesterol synthetic pathway, which may be downregulated in patients with *APOEε4* in response to altered lipoprotein metabolism and hepatic uptake[46]. In another study, the *APOEε4* allele was also associated with lower CRP but not white blood cell count[47]. Further mechanistic studies are needed to explain the link.

Our study is the first to report that in CD patients, the *APOEε4* allele is associated with higher median levels of albumins at the worst flare. Albumin level is negatively correlated with the extent of the inflammatory response, which is caused by a hypercatabolic state and a decrease of albumin synthesis in the liver[48]. Tumour necrosis factor-α inhibits albumin expression causing hypoalbuminemia[48] , a state associated with IBD activity, unresponsiveness to treatment, and increased risk of colectomy in UC. Patients with hypoalbuminemia had a higher likelihood of having more than two courses of corticosteroids, thiopurine, or anti-tumour necrosis factor treatment[49]. In CD, albumin levels were reported as a marker of postoperative complications[50] and active clinical disease[51]. Low albumin level together with high CRP may correlate with an increased inflammatory response[52]. In the study of Sayar *et al*[53], the area under the curve values for severe UC were 0.883 for albumin levels (cut-off 3.6 g/dL) and 0.941 for CRP/albumin ratio (cut-off 0.6)[52]. Given these data, the results of our study may suggest that the *APOEε4* allele is associated with a milder disease course of CD. The association of the *APOEε2* allele with lower PCDAI scores and fewer days of hospitalisation due to relapse might suggest a protective role of this allele on disease severity. However, this relationship is more complicated as we found that the *APOEε2* allele is also associated with a younger age at first surgery. This finding should be verified, preferably in a group of adult patients with a longer disease course and higher surgery rates.

The biology of APOE in IBD has not been fully elucidated, but recent studies have shown that the *APOE* transcript is overexpressed in paediatric IBD patients[53]. Studies in colonic epithelial cells in a mouse model showed that the apoE-mimetic peptide (COG112) inhibited the inflammatory response to *Citrobacter rodentium*[54], a bacterium known to cause colitis in mice[55]. The authors suggested this occurred by preventing the activation of nuclear factor κB[54]. Therefore, further mechanistic studies of APOE action are warranted.

A previous study on *APOE* in IBD in a group with a different genetic background (Saudi Arabia) did not focus on disease severity. Therefore, any comparisons are difficult[35]. In that study, the *APOEε4* allele was associated with the risk of developing IBD and early onset, whereas our study did not identify significant differences between *APOE* genotypes and age at diagnosis. The frequencies of *APOEε3ε3* genotype were lower in IBD patients in comparison to controls, which is consistent with the above-mentioned report[35].

The present study involved a large multicentre paediatric cohort, including a comprehensive clinical description, which allowed a detailed genotype-phenotype analysis. However, defining the global severity of the disease course remains challenging, especially in diseases with such a differentiated clinical presentation. The major limitation of this study is related to the retrospective character of the data collection regarding diagnosis and the worst flare. Need for surgery, which is one of the most crucial measures of disease course, would require longer follow-up in order to describe disease severity. Although we did not include a control group, *APOE* polymorphisms in healthy subjects have been studied in the Polish population[40-42,56], which allowed us to estimate whether there was any frequency distribution difference.

**CONCLUSION**

*APOE* polymorphisms are associated with the risk of developing IBD and seem to be associated with the clinical expression of the disease and applied treatment (with inflammatory markers and nutritional status, disease activity and localisation, hospitalisations). However, the clinical relevance of the differences identified is relatively modest.

**ARTICLE HIGHLIGHTS**

***Research background***

Apolipoprotein E (*APOE*)polymorphisms were previously reported to be linked with the risk of developing inflammatory bowel diseases (IBD).

***Research motivation***

No data on the relationship between *APOE* polymorphisms and disease severity are available.

***Research objectives***

This study aimed to investigate the link between *APOE* variants and disease severity in IBD.

***Research methods***

The TaqMan hydrolysis probe assay was used to genotype 406 patients with IBD (192 had ulcerative colitis and 214 had Crohn’s disease). Clinical expression involved disease activity scales, albumin and C-reactive protein levels, disease localisation and behaviour, and treatment with the time and age of the first intervention. The number of hospitalisations and days spent in hospital due to exacerbation as well as the number of relapses and severe relapses were also estimated.

***Research results***

Ulcerative colitis patients with the *APOEε4* allele had the lowest C-reactive protein values both at diagnosis (*P* = 0.0435) and the worst flare (*P* = 0.0013) compared to patients with the *APOEε2* allele and genotype *APOEε3/ε3*. Crohn’s disease patients with the *APOEε2* allele scored lower on the Pediatric Crohn’s Disease Activity Index at diagnosis (*P* = 0.0204). All IBD patients with the *APOEε2* allele spent fewer days in the hospital due to relapse (*P* = 0.0440).

***Research conclusions***

The *APOE* genotype seems to be associated with some indices of disease course such as inflammatory markers, disease activity, and applied treatment. However, the clinical significance of the differences identified remains modest.

***Research perspectives***

Further mechanistic studies of APOE action in IBD are warranted.

**REFERENCES**

1 **Wawrzyniak M**, Scharl M. Genetics and epigenetics of inflammatory bowel disease. *Swiss Med Wkly* 2018; **148**: w14671 [PMID: 30378641 DOI: 10.4414/smw.2018.14671]

2 **Brant SR**. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. *Clin Gastroenterol Hepatol* 2013; **11**: 22-26 [PMID: 23131344 DOI: 10.1016/j.cgh.2012.11.001]

3 **Jostins L**, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012; **491**: 119-124 [PMID: 23128233 DOI: 10.1038/nature11582]

4 **de Lange KM**, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat Genet* 2017; **49**: 256-261 [PMID: 28067908 DOI: 10.1038/ng.3760]

5 **Lichtenstein GR**, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s disease behavior. *Inflamm Bowel Dis* 2011; **17**: 2488-2496 [PMID: 21391291 DOI: 10.1002/ibd.21661]

6 **Brant SR**, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. *Inflamm Bowel Dis* 2003; **9**: 281-289 [PMID: 14555911 DOI: 10.1097/00054725-200309000-00001]

7 **Abreu MT**, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. *Gastroenterology* 2002; **123**: 679-688 [PMID: 12198692 DOI: 10.1053/gast.2002.35393]

8 **Cleynen I**, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, Crusius BJ, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, Danese S, van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. *Gut* 2013; **62**: 1556-1565 [PMID: 23263249 DOI: 10.1136/gutjnl-2011-300777]

9 **Alvarez-Lobos M**, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yagüe J, Panés J. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. *Ann Surg* 2005; **242**: 693-700 [PMID: 16244543 DOI: 10.1097/01.sla.0000186173.14696.ea]

10 **Adler J**, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. *Am J Gastroenterol* 2011; **106**: 699-712 [PMID: 21343918 DOI: 10.1038/ajg.2011.19]

11 **Corder EH**, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. *Science* 1993; **261**: 921-923 [PMID: 8346443 DOI: 10.1126/science.8346443]

12 **Mahley RW**, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet* 2000; **1**: 507-537 [PMID: 11701639 DOI: 10.1146/annurev.genom.1.1.507]

13 **Hubacek JA**, Peasey A, Pikhart H, Stavek P, Kubinova R, Marmot M, Bobak M. APOE polymorphism and its effect on plasma C-reactive protein levels in a large general population sample. *Hum Immunol* 2010; **71**: 304-308 [PMID: 20074603 DOI: 10.1016/j.humimm.2010.01.008]

14 **Zhang HL**, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Dev Immunol* 2010; **2010**: 186813 [PMID: 20613949 DOI: 10.1155/2010/186813]

15 **Zhang H**, Wu LM, Wu J. Cross-talk between apolipoprotein E and cytokines. *Mediators Inflamm* 2011; **2011**: 949072 [PMID: 21772670 DOI: 10.1155/2011/949072]

16 **Toms TE**, Smith JP, Panoulas VF, Blackmore H, Douglas KM, Kitas GD. Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis. *J Rheumatol* 2012; **39**: 218-225 [PMID: 22174202 DOI: 10.3899/jrheum.110683]

17 **Coto-Segura P**, Coto E, Alvarez V, Morales B, Soto-Sánchez J, Corao AI, Santos-Juanes J. Apolipoprotein epsilon4 allele is associated with psoriasis severity. *Arch Dermatol Res* 2010; **302**: 145-149 [PMID: 19911187 DOI: 10.1007/s00403-009-1002-2]

18 **Furumoto H**, Nakamura K, Imamura T, Hamamoto Y, Shimizu T, Muto M, Asagami C. Association of apolipoprotein allele epsilon 2 with psoriasis vulgaris in Japanese population. *Arch Dermatol Res* 1997; **289**: 497-500 [PMID: 9341968 DOI: 10.1007/s004030050229]

19 **Avila EM**, Holdsworth G, Sasaki N, Jackson RL, Harmony JA. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. *J Biol Chem* 1982; **257**: 5900-5909 [PMID: 7068619]

20 **Schumacher K**, Maerker-Alzer G, Wehmer U. A lymphocyte-inhibiting factor isolated from normal human liver. *Nature* 1974; **251**: 655-656 [PMID: 4422189 DOI: 10.1038/251655a0]

21 **Hui DY**, Harmony JA. Phosphatidylinositol turnover in mitogen-activated lymphocytes. Suppression by low-density lipoproteins. *Biochem J* 1980; **192**: 91-98 [PMID: 6796039 DOI: 10.1042/bj1920091]

22 **Hui DY**, Harmony JA, Innerarity TL, Mahley RW. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. *J Biol Chem* 1980; **255**: 11775-11781 [PMID: 7440569]

23 **Pepe MG**, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. *J Immunol* 1986; **136**: 3716-3723 [PMID: 3701060]

24 **Mistry MJ**, Clay MA, Kelly ME, Steiner MA, Harmony JA. Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. *Cell Immunol* 1995; **160**: 14-23 [PMID: 7842480 DOI: 10.1016/0008-8749(95)80004-3]

25 **Terkeltaub RA**, Dyer CA, Martin J, Curtiss LK. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. *J Clin Invest* 1991; **87**: 20-26 [PMID: 1985096 DOI: 10.1172/JCI114971]

26 **Vitek MP**, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. *Neurobiol Aging* 2009; **30**: 1350-1360 [PMID: 18155324 DOI: 10.1016/j.neurobiolaging.2007.11.014]

27 **Colton CA**, Brown CM, Czapiga M, Vitek MP. Apolipoprotein-E allele-specific regulation of nitric oxide production. *Ann N Y Acad Sci* 2002; **962**: 212-225 [PMID: 12076977 DOI: 10.1111/j.1749-6632.2002.tb04070.x]

28 **Colton CA**, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. *Neurobiol Aging* 2002; **23**: 777-785 [PMID: 12392781 DOI: 10.1016/s0197-4580(02)00016-7]

29 **Maezawa I**, Nivison M, Montine KS, Maeda N, Montine TJ. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. *FASEB J* 2006; **20**: 797-799 [PMID: 16481366 DOI: 10.1096/fj.05-5423fje]

30 **Saura J**, Petegnief V, Wu X, Liang Y, Paul SM. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. *J Neurochem* 2003; **85**: 1455-1467 [PMID: 12787065 DOI: 10.1046/j.1471-4159.2003.01788.x]

31 **Werb Z**, Chin JR. Apoprotein E is synthesized and secreted by resident and thioglycollate-elicited macrophages but not by pyran copolymer- or bacillus Calmette-Guerin-activated macrophages. *J Exp Med* 1983; **158**: 1272-1293 [PMID: 6619735 DOI: 10.1084/jem.158.4.1272]

32 **Levy E**, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, Seidman E. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. *Am J Clin Nutr* 2000; **71**: 807-815 [PMID: 10702177 DOI: 10.1093/ajcn/71.3.807]

33 **Hrabovský V**, Zadák Z, Bláha V, Hyspler R, Karlík T, Martínek A, Mendlová A. Cholesterol metabolism in active Crohn’s disease. *Wien Klin Wochenschr* 2009; **121**: 270-275 [PMID: 19562284 DOI: 10.1007/s00508-009-1150-6]

34 **Gazouli M**, Anagnostopoulos AK, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G, Theodoropoulos GE, Anagnou NP, Tsangaris GT. Serum protein profile of Crohn’s disease treated with infliximab. *J Crohns Colitis* 2013; **7**: e461-e470 [PMID: 23562004 DOI: 10.1016/j.crohns.2013.02.021]

35 **Al-Meghaiseeb ES**, Al-Otaibi MM, Al-Robayan A, Al-Amro R, Al-Malki AS, Arfin M, Al-Asmari AK. Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease. *World J Gastroenterol* 2015; **21**: 897-904 [PMID: 25624723 DOI: 10.3748/wjg.v21.i3.897]

36 **IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.** Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. *J Pediatr Gastroenterol Nutr* 2005; **41**: 1-7 [PMID: 15990620 DOI: 10.1097/01.mpg.0000163736.30261.82]

37 **Van Assche G**, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. *J Crohns Colitis* 2010; **4**: 7-27 [PMID: 21122488 DOI: 10.1016/j.crohns.2009.12.003]

38 **Best WR**, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701]

39 **Assa A**, Rinawi F, Shamir R. The Long-Term Predictive Properties of the Paris Classification in Paediatric Inflammatory Bowel Disease Patients. *J Crohns Colitis* 2018; **12**: 39-47 [PMID: 28961726 DOI: 10.1093/ecco-jcc/jjx125]

40 **Jasienska G**, Ellison PT, Galbarczyk A, Jasienski M, Kalemba-Drozdz M, Kapiszewska M, Nenko I, Thune I, Ziomkiewicz A. Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: a case of antagonistic pleiotropy? *Proc Biol Sci* 2015; **282**: 20142395 [PMID: 25673673 DOI: 10.1098/rspb.2014.2395]

41 **Kowalska A**, Wiechmann I, Walter H. Genetic variability of apolipoprotein E in a Polish population. *Hum Biol* 1998; **70**: 1093-1099 [PMID: 9825598]

42 **Bednarska-Makaruk M**, Broda G, Kurjata P, Rodo M, Roszczynko M, Rywik S, Wehr H. Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish population group. *Eur J Epidemiol* 2001; **17**: 789-792 [PMID: 12086099 DOI: 10.1023/a:1015657709060]

43 **Bojar I**, Owoc J, Wójcik-Fatla A, Raszewski G, Stančiak J, Raczkiewicz D. Cognitive functions, lipid profile, and Apolipoprotein E gene polymorphism in postmenopausal women. *Ann Agric Environ Med* 2015; **22**: 313-319 [PMID: 26094530 DOI: 10.5604/12321966.1152086]

44 **Mänttäri M**, Manninen V, Palosuo T, Ehnholm C. Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men. *Atherosclerosis* 2001; **156**: 237-238 [PMID: 11417521 DOI: 10.1016/s0021-9150(01)00480-4]

45 **Tziakas DN**, Chalikias GK, Antonoglou CO, Veletza S, Tentes IK, Kortsaris AX, Hatseras DI, Kaski JC. Apolipoprotein E genotype and circulating interleukin-10 Levels in patients with stable and unstable coronary artery disease. *J Am Coll Cardiol* 2006; **48**: 2471-2481 [PMID: 17174184 DOI: 10.1016/j.jacc.2006.08.032]

46 **Judson R**, Brain C, Dain B, Windemuth A, Ruaño G, Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. *Atherosclerosis* 2004; **177**: 345-351 [PMID: 15530909 DOI: 10.1016/j.atherosclerosis.2004.07.012]

47 **März W**, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). *Eur Heart J* 2004; **25**: 2109-2119 [PMID: 15571826 DOI: 10.1016/j.ehj.2004.08.024]

48 **Yun YW**, Kweon SS, Choi JS, Rhee JA, Lee YH, Nam HS, Jeong SK, Park KS, Ryu SY, Choi SW, Kim HN, Cauley JA, Shin MH. APOE Polymorphism Is Associated with C-reactive Protein Levels but Not with White Blood Cell Count: Dong-gu Study and Namwon Study. *J Korean Med Sci* 2015; **30**: 860-865 [PMID: 26130946 DOI: 10.3346/jkms.2015.30.7.860]

49 **Chojkier M**. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. *J Clin Gastroenterol* 2005; **39**: S143-S146 [PMID: 15758650 DOI: 10.1097/01.mcg.0000155514.17715.39]

50 **Khan N**, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. *World J Gastroenterol* 2017; **23**: 8008-8016 [PMID: 29259376 DOI: 10.3748/wjg.v23.i45.8008]

51 **Müller C**, Stift A, Argeny S, Bergmann M, Gnant M, Marolt S, Unger L, Riss S. Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn’s disease than albumin alone - A retrospective cohort study. *PLoS One* 2018; **13**: e0206911 [PMID: 30422980 DOI: 10.1371/journal.pone.0206911]

52 **Harris** **P,** Matin T, Zhang N, Talha M. 778 Association Between Serum Albumin Levels and the Rate of Active Crohn’s Disease in Patients Seen at a Tertiary Care IBD Center. *Am J Gastroenterol* 2019; **114**: S452-S452 [DOI: 10.14309/01.ajg.0000592648.75273.6d]

53 **Sayar S**, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. *North Clin Istanb* 2020; **7**: 49-55 [PMID: 32232203 DOI: 10.14744/nci.2018.78800]

54 **Ostrowski J**, Dabrowska M, Lazowska I, Paziewska A, Balabas A, Kluska A, Kulecka M, Karczmarski J, Ambrozkiewicz F, Piatkowska M, Goryca K, Zeber-Lubecka N, Kierkus J, Socha P, Lodyga M, Klopocka M, Iwanczak B, Bak-Drabik K, Walkowiak J, Radwan P, Grzybowska-Chlebowczyk U, Korczowski B, Starzynska T, Mikula M. Redefining the Practical Utility of Blood Transcriptome Biomarkers in Inflammatory Bowel Diseases. *J Crohns Colitis* 2019; **13**: 626-633 [PMID: 30541017 DOI: 10.1093/ecco-jcc/jjy205]

55 **Singh K**, Chaturvedi R, Asim M, Barry DP, Lewis ND, Vitek MP, Wilson KT. The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. *J Biol Chem* 2008; **283**: 16752-16761 [PMID: 18417477 DOI: 10.1074/jbc.M710530200]

56 **Gobert AP**, Cheng Y, Akhtar M, Mersey BD, Blumberg DR, Cross RK, Chaturvedi R, Drachenberg CB, Boucher JL, Hacker A, Casero RA Jr, Wilson KT. Protective role of arginase in a mouse model of colitis. *J Immunol* 2004; **173**: 2109-2117 [PMID: 15265947 DOI: 10.4049/jimmunol.173.3.2109]

**Footnotes**

**Institutional review board statement:** The study obtained the approval of the Bioethical Committee at Poznań University of Medical Sciences (960/15 with the associated amendments).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 18, 2020

**First decision:** November 3, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Tsibouris P, Tsujinaka S **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Table 1 Demographic and clinical expression of Crohn’s disease and ulcerative colitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables median (IQR) or *n* (%)** | ***n*** | **Crohn’s disease** | **Ulcerative colitis** | ***P* value** |
| Age in yr |
| At inclusion | 397 | 15.18 (13.32-17.05) | 15.11 (11.70-16.75) | 0.044 |
| At diagnosis | 404 | 12.58 (10.02-14.32) | 12.14 (7.89-14.94) | 0.365 |
| At worst flare | 355 | 13.63 (11.54-15.85) | 13.76 (10.13-15.84) | 0.244 |
| Duration of the disease (yr) | 390 | 2.23 (0.82-4.25) | 1.88 (0.36-3.77) | 0.239 |
| Female | 173 | 86 (40.2) | 87 (45.3) | 0.297 |
| Nutritional status |
| Weight at diagnosis in kg | 387 | 38.0 (27.0-49.8) | 40.0 (27.8-53.9) | 0.490 |
| Weight at diagnosis, z score | 383 | -0.82 [(-1.39)-(-0.04)] | -0.51 [(-1.12)-0.22] | 0.003 |
| Height at diagnosis in cm | 382 | 151.0 (137.0-164.5) | 152.0 (130.5-168.3) | 0.718 |
| Height at diagnosis, z score | 378 | -0.37 [(-1.29)-0.47] | 0.06 [(-0.67)-0.81] | 0.001 |
| Body mass index at diagnosis in kg/m2 | 382 | 16.6 (14.5-18.4) | 17.4 (15.5-19.3) | 0.019 |
| Body mass index at diagnosis, z score | 378 | -0.79 [(-1.47)-(-0.04)] | -0.49 [(-1.00)-0.16] | 0.006 |
| Albumin level at diagnosis in g/dL | 345 | 3.90 (3.51-4.25) | 4.10 (3.70-4.40) | < 0.003 |
| Parameter of inflammation |
| CRP at diagnosis in mg/L1 | 386 | 12.94 (2.10-29.25) | 2.24 (0.50-10.80) | < 0.001 |
| CRP at worst flare in mg/L | 347 | 13.95 (3.03-32.43) | 2.70 (0.63-13.44) | < 0.001 |
| Disease activity scales |  |  |  |  |
| PCDAI/PUCAI at diagnosis | 190/166 | 32 (23-48) | 45 (28-60) |  |
| PCDAI/PUCAI at worst flare | 170/155 | 40 (30-53) | 50 (35-65) |  |
| Treatment |
| Systemic steroids2 | 406 | 115 (53.7) | 138 (71.9) | < 0.001 |
| Immunosuppressive treatment3 | 405 | 168 (78.5) | 112 (58.6) | < 0.001 |
| Biological therapy4 | 406 | 107 (50.0) | 49 (25.5) | < 0.001 |
| Operative treatment5 | 406 | 29 (13.6) | 4 (2.1) | < 0.001 |

1C-reactive protein reference range 0-5 mg/L; 2Systemic steroid therapy included: methylprednisolone, prednisone, hydrocortisone; 3Immunosuppressive and anti-inflammatory agents included: azathioprine, methotrexate, mercaptopurine, cyclosporine, mycophenolate mofetil, tacrolimus, sulfasalazine; 4Biological agents included: infliximab, adalimumab, golimumab, vedolizumab; 5Only surgery related to inflammatory bowel disease-specific problems (*e.g.*, colectomy, resection, fistula, perforation, abscess) was included. CRP: C-reactive protein; IBD: Inflammatory bowel disease; IQR: Interquartile range; PCDAI: Pediatric Crohn’s Disease Activity Index; PUCAI: Pediatric Ulcerative Colitis Activity Index.

**Table 2 Apolipoprotein E genotype and allele distribution compared between ulcerative colitis and Crohn’s disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Genotype/allele** | **UC, *n* = 192** | **CD, *n* = 214** | ***P* value, two-tailed Fisher exact** | **Odds ratio (95%CI)** |
| ε3/ε3 | 118 | 135 | 0.7590 | 0.93 (0.62-1.40) |
| ε3/ε4 | 47 | 41 | 0.2278 | 1.37 (0.85-2.20) |
| ε2/ε3 | 18 | 35 | 0.0397 | 0.53 (0.29-0.97) |
| ε3+ | 183 | 211 | 0.0757 | 0.29 (0.08-1.08) |
| ε4+ | 54 | 43 | 0.0629 | 1.56 (0.98-2.46) |
| ε2+ | 24 | 37 | 0.2108 | 0.68 (0.39-1.19) |

CD: Crohn’s disease; CI: Confidence interval; UC: Ulcerative colitis.

**Table 3 Clinical characteristics in patients with ulcerative colitis depending on major apolipoprotein E genotypes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables median (IQR) or *n* (%)** | ***n*** | **ε2/ε3** | **ε3/ε3** | **ε3/ε4** | ***P* value** |
| Age in yr |
| At inclusion | 184 | 15.7 (12.5-16.9) | 15.3 (11.9-16.9) | 14.3 (11.5-16.3) | 0.2464 |
| At diagnosis | 191 | 11.4 (7.9-14.6) | 12.4 (7.9-15.0) | 12.4 (8.2-14.9) | 0.9070 |
| At worst flare | 171 | 14.6 (9.9-16.4) | 13.7 (10.4-16.0) | 13.7 (10.0-15.7) | 0.7255 |
| Duration of the disease in yr | 179 | 3.0 (1.4-6.2) | 1.9 (0.4-3.5) | 1.2 (0.0-3.5) | 0.0868 |
| Nutritional status |
| Weight at diagnosis in kg | 180 | 40.0 (28.8-59.5) | 39.0 (27.8-54.0) | 43.8 (29.5-53.4) | 0.9704 |
| Weight at diagnosis, z score | 179 | -0.20 [(-0.86)-0.43] | -0.5 [(-1.1)-0.1] | -0.24 [(-0.95)-0.63] | 0.3037 |
| Height at diagnosis in cm | 175 | 146.5 (129.0-169.0) | 153.0 (131.0-168.5) | 156.0 (131.5-169.0) | 0.9175 |
| Height at diagnosis, z score | 174 | 0.12 [(-0.62)-0.75] | 0.09 [(-0.69)-0.79] | 0.22 [(-0.44)-1.06] | 0.5823 |
| Body mass index at diagnosis in kg/m2 | 175 | 17.61 (16.02-19.74) | 17.0 (15.4-19.1) | 17.9 (15.4-20.3) | 0.5121 |
| Body mass index at diagnosis, z score | 174 | -0.11 [(-0.70)-0.29)] | -0.56 [(-0.99)-0.11] | -0.30 [(-1.12)-0.56] | 0.2293 |
| Weight at worst flare in kg | 164 | 46.1 (31.6-62.0) | 46.2 (31.9-55.6) | 50.0 (28.0-61.0) | 0.9600 |
| Weight at worst flare, z score | 161 | -0.33 [(-1.00)-0.56] | -0.58 [(-0.95)-0.16] | -0.52 [(-0.90)-0.40] | 0.6559 |
| Height at worst flare in cm | 162 | 162.5 (138.5-173.5) | 159.0 (140.9-171.0) | 160.0 (135.0-172.0) | 0.9688 |
| Height at worst flare, z score | 161 | 0.11 [(-0.72)-1.16] | -0.09 [(-0.62)-0.78] | 0.06 [(-0.62)-0.89] | 0.8376 |
| Body mass index at worst flare in kg/m2 | 160 | 18.20 (16.47-19.74) | 17.36 (15.75-19.71) | 17.93 (15.89-20.96) | 0.6013 |
| Body mass index at worst flare, z score | 159 | -0.22 [(-1.16)-0.14] | -0.68 [(-1.10)-0.16] | -0.43 [(-1.12)-0.63] | 0.6789 |
| Albumin level |
| At diagnosis in g/dL | 159 | 4.2 (4.0-4.6) | 4.1 (3.7-4.4) | 4.1 (3.6-4.4) | 0.2569 |
| At worst flare in g/ dL | 148 | 4.3 (4.0-4.7) | 4.1 (3.6-4.4) | 4.2 (4.0-4.4) | 0.3488 |
| Parameter of inflammation |
| CRP at diagnosis in mg/L | 178 | 3.8 (0.7-6.6) | 2.5 (0.7-12.2) | 1.1 (0.2-8.0) | 0.0515 |
| CRP at worst flare in mg/L | 162 | 2.1 (1.1-23.3) | 3.7 (1.1-19.0) | 0.8 (0.3-2.9) | 0.0012 |
| Disease activity scales |
| PUCAI at diagnosis | 166 | 40 (18-55) | 45 (30-60) | 50 (25-60) | 0.5144 |
| PUCAI at worst flare | 155 | 48 (20-65) | 55 (40-65) | 50 (30-65) | 0.3766 |
| Disease localisation and behaviour |
| E1 at diagnosis | 19/192 | 3 (16.7) | 10 (8.5) | 6 (12.8) | 0.4694 |
| E2 at diagnosis | 33/192 | 8 (44.4) | 16 (13.6) | 9 (19.1) | 0.0063 |
| E3 at diagnosis | 28/192 | 1 (5.6) | 18 (15.3) | 9 (19.1) | 0.3953 |
| E4 at diagnosis | 83/192 | 5 (27.8) | 60 (50.8) | 18 (38.3) | 0.0990 |
| S0 at diagnosis | 110/192 | 13 (72.2) | 69 (58.5) | 28 (59.6) | 0.5383 |
| S1 at diagnosis | 37/192 | 3 (16.7) | 23 (19.5) | 11 (23.4) | 0.7885 |
| E1 at worst flare | 9/192 | 1 (5.6) | 4 (3.4) | 4 (8.5) | 0.3863 |
| E2 at worst flare | 27/192 | 3 (16.7) | 18 (15.3) | 6 (12.8) | 0.8943 |
| E3 at worst flare | 23/192 | 3 (16.7) | 16 (13.6) | 4 (8.5) | 0.5814 |
| E4 at worst flare | 75/192 | 7 (38.9) | 50 (42.4) | 18 (38.3) | 0.8750 |
| S0 at worst flare | 83/192 | 9 (50.0) | 52 (44.1) | 22 (46.8) | 0.8713 |
| S1 at worst flare | 49/192 | 5 (27.8) | 34 (28.8) | 10 (21.3) | 0.6114 |
| Treatment |
| Systemic steroids1 | 192 | 11 (61.1) | 92 (78.0) | 29 (61.7) | 0.0599 |
| Number of courses of steroid treatment | 190 | 1 (0-2) | 1 (1-2) | 1 (0-2) | 0.0672 |
| Immunosuppressive treatment2 | 191 | 9 (50.0) | 74 (63.2) | 25 (53.2) | 0.3451 |
| Number of immunosuppressants | 191 | 1 (0-1) | 1 (0-1) | 1 (0-1) | 0.2572 |
| Time-to-first dose of immunosuppressive treatment in mo | 109 | 3.0 (2.0-17.0) | 4.0 (0.0-10.0) | 2.8 (0.0-8.0) | 0.4356 |
| Age at first intake of immunosuppressive treatment in yr | 109 | 14.7 (10.4-16.1) | 12.3 (7.8-14.1) | 11.0 (7.3-15.5) | 0.2381 |
| Biological therapy3 | 192 | 4 (22.2) | 29 (24.8) | 13 (27.7) | 0.8781 |
| Total number of biologics | 192 | 0 (0-0) | 0 (0-0) | 0 (0-1) | 0.8164 |
| Time-to-first dose of biological treatment in mo | 48 | 19.9 (12.8-50.3) | 16.4 (9.1-28.1) | 10.8 (4.0-27.7) | 0.3152 |
| Age at first biological treatment | 49 | 15.7 (14.7-15.9) | 11.5 (7.9-14.6) | 10.7 (4.5-15.5) | 0.0852 |
| Operative treatment4 | 192 | 0 (0.0) | 3 (2.5) | 1 (2.1) | 0.7893 |
| Age at first surgery in yr | 6 | 7.7 (5.9-9.6) | 14.8 (6.8-17.1) | 13.0 (10.4-15.6) | 0.2969 |
| Time-to-first surgery in mo | 4 |  | 16.7 (5.0-28.7) | 19.1 (0.9-37.4) | 1.0000 |
| Hospitalisations, if duration ≥ 1 yr |
| Hospitalisations for relapse, per 1 yr of the disease | 98 | 0.3 (0.3-0.8) | 0.6 (0.3-1.6) | 0.9 (0.5-1.3) | 0.2518 |
| Days of hospitalisation for relapse, per 1 yr of the disease | 98 | 2.5 (0.6-4.5) | 4.8 (1.8-9.3) | 7.3 (3.8-8.7) | 0.1362 |
| Relapses from diagnosis, per 1 yr of the disease | 98 | 0.3 (0.1-0.8) | 0.6 (0.3-1.2) | 0.8 (0.3-1.3) | 0.3491 |
| Severe relapses from diagnosis, per 1 yr of the disease | 100 | 0.0 (0.0-0.3) | 0.1 (0.0-0.6) | 0.2 (0.0-0.4) | 0.7150 |
| Concomitant diseases5 | 192 | 9 (50.0) | 41 (34.7) | 15 (31.9) | 0.3781 |
| Extraintestinal manifestations | 192 | 3 (16.7) | 23 (19.5) | 10 (21.3) | 0.9131 |

1Systemic steroid therapy included: methylprednisolone, prednisone, hydrocortisone; 2Immunosuppressive and anti-inflammatory agents included: azathioprine, methotrexate, mercaptopurine, cyclosporine, mycophenolate mofetil, tacrolimus, sulfasalazine; 3Biological agents included: infliximab, adalimumab, golimumab, vedolizumab; 4Only surgery related to inflammatory bowel disease-specific problems (*e.g.*,colectomy, resection, fistula, perforation, abscess) was included; 5*e.g.*,celiac disease, bronchial asthma, obesity, gastroesophageal reflux disease, epilepsy, hypothyroidism. CRP: C-reactive protein; IBD: Inflammatory bowel disease; IQR: Interquartile range; PUCAI: Pediatric Ulcerative Colitis Activity Index.

**Table 4 Clinical characteristics in patients with Crohn’s disease depending on major apolipoprotein E genotypes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables median (IQR) or *n* (%)** | ***n*** | **ε2/ε3** | **ε3/ε3** | **ε3/ε4** | ***P* value** |
| Age in yr |  |  |  |  |
| At inclusion | 213 | 15.5 (13.2-16.8) | 15.2 (13.3-17.2) | 15.2 (13.4-16.2) | 0.8055 |
| At diagnosis | 213 | 11.8 (10.1-14.6) | 12.7 (9.9-14.5) | 12.6 (10.0-13.9) | 0.8796 |
| At worst flare | 184 | 13.3 (11.6-15.2) | 13.6 (11.3-15.8) | 14.3 (12.8-15.9) | 0.5121 |
| Duration of the disease in yr | 211 | 2.8 (0.6-5.4) | 2.0 (0.8-4.0) | 2.3 (0.8-4.1) | 0.7843 |
| Nutritional status |  |  |  |  |  |
| Weight at diagnosis in kg | 207 | 38.3 (27.6-48.0) | 37.3 (25.3-49.5) | 38.4 (28.3-57.6) | 0.5360 |
| Weight at diagnosis, z score | 204 | -0.53 [(-1.02)-(-0.02)] | -0.91 [(-1.46)-(-0.12)] | -0.73 [(-1.34)-0.38] | 0.2062 |
| Height at diagnosis in cm | 207 | 148.3 (141.0-164.0) | 151.5 (134.0-164.0) | 151.3 (141.0-170.0) | 0.6757 |
| Height at diagnosis, z score | 204 | -0.17 [(-0.85)-0.51] | -0.47 [(-1.43)-0.32] | 0.05 [(-1.10)-0.96] | 0.0617 |
| Body mass index at diagnosis in kg/m2 | 207 | 16.73 (14.28-18.42) | 16.59 (14.41-18.22) | 16.40 (14.78-20.78) | 0.8397 |
| Body mass index at diagnosis, z score | 204 | -0.72 [(-1.33)-(-0.16)] | -0.79 [(-1.53)-(-0.08)] | -0.88 [(-1.29)-0.49] | 0.7878 |
| Weight at worst flare in kg | 181 | 41.8 (34.8-50.3) | 41.9 (29.6-52.6) | 46.8 (36.2-58.9) | 0.2294 |
| Weight at worst flare, z score | 178 | -0.67 [(-1.16)-0.10] | -1.14 [(-1.64)-(-0.25)] | -0.60 [(-1.22)-0.02] | 0.0756 |
| Height at worst flare in cm | 183 | 153.0 (148.5-166.0) | 158.0 (141.5-167.0) | 162.0 (148.5-171.5) | 0.3088 |
| Height at worst flare, z score | 180 | -0.15 [(-1.09)-0.61] | -0.52 [(-1.41)-0.21] | -0.24 [(-1.10)-0.43] | 0.1234 |
| Body mass index at worst flare in kg/m2 | 181 | 17.29 (15.53-18.60) | 16.89 (14.87-19.03) | 17.09 (15.56-21.74) | 0.4172 |
| Body mass index at worst flare, z score | 178 | -0.87 [(-1.38)-0.01] | -1.03 [(-1.55)-(-0.19)] | -0.53 [(-1.46)-0.49] | 0.3913 |
| Albumin level |
| At diagnosis in g/dL | 186 | 3.9 (3.7-4.3) | 3.8 (3.4-4.2) | 3.9 (3.4-4.3) | 0.5796 |
| At worst flare in g/dL | 179 | 3.9 (3.8-4.3) | 3.9 (3.4-4.1) | 3.9 (3.6-4.3) | 0.0611 |
| Parameter of inflammation |
| CRP at diagnosis in mg/L | 208 | 13.8 (0.8-40.0) | 13.0 (2.1-29.6) | 12.0 (3.4-24.9) | 0.8818 |
| CRP at worst flare in mg/L | 185 | 18.3 (1.7-31.5) | 14.0 (3.3-38.5) | 13.6 (3.2-26.8) | 0.7672 |
| Disease activity scales |
| PCDAI at diagnosis | 190 | 25 (20-35) | 35 (25-50) | 30 (25-43) | 0.0282 |
| PCDAI at worst flare | 170 | 35 (23-50) | 45 (30-53) | 38 (30-53) | 0.1898 |
| Disease localisation and behaviour |
| L1 at diagnosis | 53/213 | 9 (25.7) | 35 (26.1) | 8 (19.5) | 0.6852 |
| L2 at diagnosis | 40/213 | 9 (25.7) | 19 (14.2) | 11 (26.8) | 0.0935 |
| L3 at diagnosis | 99/213 | 13 (37.1) | 67 (50.0) | 16 (39.0) | 0.2507 |
| L4a at diagnosis | 23/213 | 4 (11.4) | 14 (10.4) | 4 (9.8) | 0.9721 |
| L4b at diagnosis | 8/213 | 1 (2.9) | 7 (5.2) | 0 (0.0) | 0.2950 |
| B1 at diagnosis | 146/213 | 24 (68.6) | 89 (66.4) | 33 (80.5) | 0.2287 |
| B2 at diagnosis | 15/213 | 3 (8.6) | 11 (8.2) | 1 (2.4) | 0.4263 |
| B3 at diagnosis | 19/213 | 3 (8.6) | 15 (11.2) | 1 (2.4) | 0.2304 |
| B2B3 at diagnosis | 4/213 | 1 (2.9) | 3 (2.2) | 0 (0.0) | 0.5927 |
| G0 at diagnosis | 145/213 | 24 (68.6) | 92 (68.7) | 29 (70.7) | 0.9667 |
| G1 at diagnosis | 33/213 | 3 (8.6) | 24 (17.9) | 6 (14.6) | 0.3921 |
| P at diagnosis | 19/213 | 0 (0.0) | 16 (11.9) | 3 (7.3) | 0.0824 |
| L1 at worst flare | 40/213 | 5 (14.3) | 26 (19.4) | 9 (22.0) | 0.6873 |
| L2 at worst flare | 27/213 | 7 (20.0) | 14 (10.4) | 6 (14.6) | 0.3007 |
| L3 at worst flare | 92/213 | 10 (28.6) | 66 (49.3) | 16 (39.0) | 0.0708 |
| L4a at worst flare | 18/213 | 3 (8.6) | 12 (9.0) | 3 (7.3) | 0.9477 |
| L4b at worst flare | 9/213 | 1 (2.9) | 5 (3.7) | 3 (7.3) | 0.5507 |
| B1 at worst flare | 114/213 | 17 (48.6) | 74 (55.2) | 23 (56.1) | 0.7549 |
| B2 at worst flare | 19/213 | 2 (5.7) | 12 (9.0) | 5 (12.2) | 0.6165 |
| B3 at worst flare | 21/213 | 1 (2.9) | 16 (11.9) | 4 (9.8) | 0.2798 |
| B2B3 at worst flare | 5/213 | 1 (2.9) | 4 (9.8) | 0 (0.0) | 0.5367 |
| G0 at worst flare | 121/213 | 18 (51.4) | 79 (59.0) | 24 (58.5) | 0.7184 |
| G1 at worst flare | 34/213 | 2 (5.7) | 24 (17.9) | 8 (19.5) | 0.1776 |
| P at worst flare | 20/213 | 0 (0.0) | 17 (12.7) | 3 (7.3) | 0.0649 |
| Treatment |
| Systemic steroids1 | 214 | 19 (34.3) | 73 (54.1) | 21 (51.2) | 0.9455 |
| Number of courses of steroid treatment | 212 | 1 (0-2) | 1 (0-2) | 1 (0-1) | 0.5535 |
| Immunosuppressive treatment2 | 214 | 25 (71.4) | 110 (81.5) | 31 (75.6) | 0.3756 |
| Number of immunosuppressants | 214 | 1 (0-1) | 1 (1-1) | 1 (1-1) | 0.2632 |
| Time-to-first dose of immunosuppressive treatment in mo | 166 | 1.3 (0.0-13.0) | 2.0 (0.0-7.0) | 1.0 (0.0-9.6) | 0.8866 |
| Age at first intake of immunosuppressive treatment in yr | 166 | 12.9 (10.3-13.9) | 13.0 (10.7-14.9) | 12.7 (9.6-14.3) | 0.6668 |
| Biological therapy3 | 214 | 15 (42.9) | 73 (54.1) | 18 (43.9) | 0.3303 |
| Total number of biologics | 214 | 0 (0-1) | 1 (0-1) | 0 (0-1) | 0.2243 |
| Time-to-first dose of biological treatment in mo | 102 | 17.8 (6.3-44.0) | 12.6 (5.6-25.9) | 13.3 (6.1-26.7) | 0.6313 |
| Age at first biological treatment | 102 | 13.8 (12.7-14.8) | 13.6 (11.3-15.3) | 14.0 (10.7-15.6) | 0.8880 |
| Operative treatment4 | 214 | 2 (5.7) | 19 (14.1) | 8 (19.5) | 0.2158 |
| Age at first surgery in yr | 30 | 11.3 (9.4-13.1) | 14.5 (12.5-16.5) | 14.9 (14.0-15.7) | 0.1698 |
| Time-to-first surgery in mo | 26 | 12.0 | 19.4 (0.0-41.1) | 25.1 (7.9-43.5) | 0.7807 |
| Hospitalisations, if duration ≥ 1 yr |  |  |  |  |  |
| Hospitalisations for relapse, per 1 yr of the disease | 133 | 0.4 (0.2-0.7) | 0.5 (0.3-0.8) | 0.4 (0.2-1.3) | 0.6615 |
| Days of hospitalisation for relapse, per 1 yr of the disease | 132 | 2.7 (0.7-5.6) | 4.7 (1.6-7.5) | 4.0 (1.1-7.6) | 0.4001 |
| Relapses from diagnosis, per 1 yr of the disease | 132 | 0.4 (0.2-0.9) | 0.5 (0.2-0.9) | 0.4 (0.2-1.4) | 0.8664 |
| Severe relapses from diagnosis, per 1 yr of the disease | 129 | 0.0 (0.0-0.3) | 0.2 (0.0-0.5) | 0.2 (0.0-0.5) | 0.1996 |
| Concomitant diseases5 | 214 | 16 (45.7) | 40 (29.6) | 8 (19.5) | 0.0446 |
| Extraintestinal manifestations | 214 | 7 (20.0) | 34 (25.2) | 11 (26.8) | 0.7660 |

1Systemic steroid therapy included: methylprednisolone, prednisone, hydrocortisone; 2Immunosuppressive and anti-inflammatory agents included: azathioprine, methotrexate, mercaptopurine, cyclosporine, mycophenolate mofetil, tacrolimus, sulfasalazine; 3Biological agents included: infliximab, adalimumab, golimumab, vedolizumab; 4Only surgery related to inflammatory bowel disease-specific problems (*e.g.* colectomy, resection, fistula, perforation, abscess) was included; 5*e.g.* celiac disease, bronchial asthma, obesity, gastroesophageal reflux disease, epilepsy, hypothyroidism. CRP: C-reactive protein; IQR: Interquartile range; PCDAI: Pediatric Crohn’s Disease Activity Index.

**Table 5 Summary of relevant findings depending on apolipoprotein E genotypes and alleles**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables median (IQR) or *n* (%)** | ***n*** | ***ε3/ε3*** | ***APOE****ε****2-*positive** | ***APOE****ε****4*-positive** | ***P* value** |
| IBD |
| Albumin level at worst flare in g/dL | 327 | 3.9 (3.4-4.3) | 4.0 (3.9-4.5) | 4.1 (3.8-4.4) | 0.0176a |
| CRP at worst flare in mg/L | 347 | 7.7 (1.9-31.3) | 4.3 (1.1-28.3) | 3.2 (0.5-16.7) | 0.0146b |
| Age at first surgery in yr | 36 | 14.5 (11.7-16.7) | 9.5 (7.7-11.4) | 14.9 (14.0-15.6) | 0.0378 |
| Days of hospitalisation for relapse, per 1 yr of the disease | 230 | 4.7 (1.6-8.3) | 2.2 (0.7-4.8) | 6.1 (1.7-8.7) | 0.0440c |
| CD |
| Albumin level at worst flare in g/dL | 327 | 3.9 (3.4-4.1) | 3.9 (3.8-4.4) | 4.4 (3.6-4.3) | 0.0363 |
| PCDAI at diagnosis | 190 | 35 (25-50) | 25 (20-35) | 30 (25-45) | 0.0204c |
| Height at diagnosis, z score | 378 | -0.47 [(-1.43)-0.32] | -0.16 [(-0.85)-0.61] | 0.00 [(-1.10)-0.96] | 0.0482 |
| UC |
| CRP at diagnosis in mg/L | 386 | 2.5 (0.7-12.2) | 3.8 (0.8-7.3) | 1.1 (0.2-8.2) | 0.0435 |
| CRP at worst flare in mg/L | 347 | 3.7 (1.1-19.0) | 2.1 (1.8-7.3) | 0.9 (0.3-3.6) | 0.0013 |
| Age at first biological treatment | 151 | 11.5 (7.9-14.6) | 15.7 (15.3-15.7) | 10.7 (4.8-15.5) | 0.0432 |
| E2 at diagnosis | 192 | 16 (13.6) | 8 (40.0) | 9 (18.0) | 0.0160 |

aPost hoc APOEε3ε3 vs APOEε2-positive P = 0.0383 (Bonferroni and Holm); APOEε3ε3 vs APOEε4-positive P = 0.0417 (Bonferroni) and P = 0.0383 (Holm); bPost hoc APOEε3ε3 vs APOEε4-positive P = 0.0056 (Bonferroni and Holm); cAPOEε3ε3 vs APOEε2-positive P = 0.0534 (Bonferroni) and P = 0.0356 (Holm), APOEε2-positive vs APOEε4-positive P = 0.0216 (Bonferroni and Holm). CD: Crohn’s disease; CRP: C-reactive protein; IBD: Inflammatory bowel disease; PCDAI: Pediatric Crohn’s Disease Activity Index; UC: Ulcerative colitis.